145 related articles for article (PubMed ID: 24605557)
41. Precision Medicine for Diffuse Large B-cell Lymphoma.
Lim MS; Elenitoba-Johnson KS
Clin Cancer Res; 2016 Jun; 22(12):2829-31. PubMed ID: 26988247
[TBL] [Abstract][Full Text] [Related]
42. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
Molloy MP; Engel A
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
[No Abstract] [Full Text] [Related]
43. Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy.
Wirth F; Zahra G; Xuereb RG; Barbara C; Fenech A; Azzopardi LM
Int J Clin Pharm; 2016 Apr; 38(2):414-20. PubMed ID: 26980150
[TBL] [Abstract][Full Text] [Related]
44. Towards a personalized treatment of head and neck cancer.
Gross AM; Cohen EE
Am Soc Clin Oncol Educ Book; 2015; ():28-32. PubMed ID: 25993138
[No Abstract] [Full Text] [Related]
45. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
46. Editorial: Targeting of Cancer Cells and Tumor Microenvironment: Perspectives for Personalized Therapy.
Kzhyshkowska J; Bizzarri M; Apte R; Cherdyntseva N
Curr Pharm Des; 2017; 23(32):4703-4704. PubMed ID: 29283049
[No Abstract] [Full Text] [Related]
47. Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.
Niklinski J; Kretowski A; Moniuszko M; Reszec J; Michalska-Falkowska A; Niemira M; Ciborowski M; Charkiewicz R; Jurgilewicz D; Kozlowski M; Ramlau R; Piwkowski C; Kwasniewski M; Kaczmarek M; Ciereszko A; Wasniewski T; Mroz R; Naumnik W; Sierko E; Paczkowska M; Kisluk J; Sulewska A; Cybulski A; Mariak Z; Kedra B; Szamatowicz J; Kurzawa P; Minarowski L; Charkiewicz AE; Mroczko B; Malyszko J; Manegold C; Pilz L; Allgayer H; Abba ML; Juhl H; Koch F;
Adv Med Sci; 2017 Sep; 62(2):405-413. PubMed ID: 28646744
[TBL] [Abstract][Full Text] [Related]
48. Chronic lymphocytic leukaemia genomics and the precision medicine era.
Ghamlouch H; Nguyen-Khac F; Bernard OA
Br J Haematol; 2017 Sep; 178(6):852-870. PubMed ID: 28444740
[TBL] [Abstract][Full Text] [Related]
49. Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine.
Tsimberidou AM
Curr Probl Cancer; 2017; 41(3):176-181. PubMed ID: 28410846
[TBL] [Abstract][Full Text] [Related]
50. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
51. Multiplex assay for multiomics advances in personalized-precision medicine.
Popa ML; Albulescu R; Neagu M; Hinescu ME; Tanase C
J Immunoassay Immunochem; 2019; 40(1):3-25. PubMed ID: 30632882
[TBL] [Abstract][Full Text] [Related]
52. Real-world data in the molecular era-finding the reality in the real world.
Dickson DJ; Pfeifer JD
Clin Pharmacol Ther; 2016 Feb; 99(2):186-97. PubMed ID: 26565654
[TBL] [Abstract][Full Text] [Related]
53. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics.
Lu DY; Qu RX; Lu TR; Wu HY
Rev Recent Clin Trials; 2017; 12(2):101-110. PubMed ID: 28190390
[TBL] [Abstract][Full Text] [Related]
54. Precision Medicine: The new era in medicine.
Twilt M
EBioMedicine; 2016 Feb; 4():24-5. PubMed ID: 26981568
[No Abstract] [Full Text] [Related]
55. An appraisal of drug development timelines in the Era of precision oncology.
Jardim DL; Schwaederle M; Hong DS; Kurzrock R
Oncotarget; 2016 Aug; 7(33):53037-53046. PubMed ID: 27419632
[TBL] [Abstract][Full Text] [Related]
56. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
[TBL] [Abstract][Full Text] [Related]
57. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
58. Measure for Measure: Biomarker standards and transparency.
FitzGerald GA
Sci Transl Med; 2016 Jun; 8(343):343fs10. PubMed ID: 27306662
[TBL] [Abstract][Full Text] [Related]
59. Personalized targeted therapy for esophageal squamous cell carcinoma.
Kang X; Chen K; Li Y; Li J; D'Amico TA; Chen X
World J Gastroenterol; 2015 Jul; 21(25):7648-58. PubMed ID: 26167067
[TBL] [Abstract][Full Text] [Related]
60. Does personalized medicine exist and can you test it in a clinical trial?
Sandercock PA
Int J Stroke; 2015 Oct; 10(7):994-9. PubMed ID: 26282857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
